Cart
sales@molnova.com
CFI-400945
CAS No. 1338806-73-7
CFI-400945( —— )
Catalog No. M23495 CAS No. 1338806-73-7
CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 93 | In Stock |
|
| 5MG | 84 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 280 | In Stock |
|
| 50MG | 477 | In Stock |
|
| 100MG | 761 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCFI-400945
-
NoteResearch use only, not for human use.
-
Brief DescriptionCFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
-
DescriptionCFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPLK
-
RecptorPLK4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1338806-73-7
-
Formula Weight534.65
-
Molecular FormulaC33H34N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO:100 mg/mL (187.04 mM;warmed with 50oC water bath);Ethanol:100 mg/mL (187.04 mM);Water:Insoluble
-
SMILESC[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Mason J , Lin D C , Wei X , et al. Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent[J]. Cancer Cell, 2014, 26(2).
molnova catalog
related products
-
Ilexsaponin A1
Ilexsaponin A shows protective effects on ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway.
-
Pyridoxine
Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body.
-
Tebanicline
Tebanicline (ABT-594, Ebanicline) acts as a partial agonist at neuronal nicotinic acetylcholine receptors, binding to both the α3β4 and the α4β2 subtypes.
